酒精性肝病的发病机理和新的治疗靶点

常彬霞; 王华; 邹正升; 李保森; 高斌

doi:10.3969/j.issn.1001-5256.2014.02.004

酒精性肝病的发病机理和新的治疗靶点

DOI: 10.3969/j.issn.1001-5256.2014.02.004

1. 解放军第302医院非感染性肝病诊疗中心
2. 美国国立卫生研究院酒精滥用与成瘾研究所(NIH/NIAAA)
3. 安徽医科大学肝病研究所

详细信息

中图分类号: R575.5
计量
- 文章访问数: 3243
- HTML全文浏览量: 19
- PDF下载量: 674
- 被引次数: 0
出版历程
- 收稿日期: 2013-09-10
- 出版日期: 2014-02-20

Pathogenesis and novel therapeutic targets of alcoholic liver disease

Center for Non - Infectious Liver Diseases, 302 Hospital of PLA

摘要

摘要:
酒精性肝病是世界范围内慢性肝病的一个主要原因,但是其发病机制尚不完全清楚,因此缺少靶向治疗的方法。总结了最近一些阐述酒精性肝病发病机制和诊断的研究,并且讨论了酒精性肝炎的几个新的治疗靶点。认为迫切须要将这些靶点转化为酒精性肝病患者的治疗方法。
- 肝疾病,酒精性 /
- 发病机制 /
- 治疗靶点 /
- 综述
Abstract:
Alcoholic liver disease ( ALD) is a leading cause of chronic liver disease worldwide; however, the pathogenesis of ALD is not fully understood and there are no targeted therapies for ALD. In this review article, we summarize the findings from recent studies that have characterized the pathogenesis and diagnosis of ALD. Several novel therapeutic targets for alcoholic hepatitis are also discussed. There is an urgent need to translate these targets into therapies for patients with ALD.
- liver diseases, alcoholic /
- pathogenesis /
- therapeutic targets /
- review

HTML全文

参考文献(41)

[1]LI YM, CHEN WX, YU CH, et al.An epidemiological survey of alcoholic liver disease in Zhejiang province[J].Chin J Hepatol, 2003, 11 (11) :647-649. (in Chinese) 厉有名, 陈卫星, 虞朝辉, 等.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志, 2003, 11 (11) :647-649.

[2]PENG L, GAN HT, OUYANG Q.A multicenter study of alcoholic liver disease in China[J].Chin J Dig, 2007, 27 (4) :231-234. (in Chinese) 彭兰, 甘华田, 欧阳钦.丝裂原活化蛋白激酶选择性抑制剂对葡聚糖硫酸钠结肠炎的影响[J].中华消化杂志, 2007, 27 (4) :231-234.

[3]CHEN SL, MENG XD, WANG BY, et al.An epidemiologic survey of alcoholic liver disease in some cities of Liaoning Province[J].J Clin Hepatol, 2010, 13 (6) :428-430. (in Chinese) 陈士林, 孟晓丹, 王炳元, 等.辽宁省部分城市酒精性肝病流行现状调查[J].实用肝脏病杂志, 2010, 13 (6) :428-430.

[4]GAO B, BATALLER R.Alcoholic liver disease:novel concepts and therapeutic targets[J].Gastroenterology, 2011, 141 (5) :1572-1585.

[5]WAGNER M, ZOLLNER G, TRAUNER M.Nuclear receptors in liver disease[J].Hepatology, 2011, 53 (3) :1023-1034.

[6]CZAJA MJ.Functions of autophagy in hepatic and pancreatic physiology and disease[J].Gastroenterology, 2011, 140 (7) :1895-1908.

[7]DING WX, LI M, CHEN X, et al.Autophagy reduces acute ethanolinduced hepatotoxicity and steatosis in mice[J].Gastroenterology, 2010, 139 (5) :1740-1752.

[8]KENDRICK SF, O’BOYLE G, MANN J, et al.Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis[J].Hepatology, 2010, 51 (6) :1988-1997.

[9]TATSUKAWA H, FUKAYA Y, FRAMPTON G, et al.Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1[J].Gastroenterology, 2009, 136 (5) :1783-1795, e10.

[10]PRITCHARD MT, McMULLEN MR, STAVITSKY AB, et al.Differential contributions of C3, C5, and decay-accelerating factor to ethanolinduced fatty liver in mice[J].Gastroenterology, 2007, 132 (3) :1117-1126.

[11] MILLER AM, WANG H, BERTOLA A, et al.Inflammation-associated IL-6/STAT3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in IL-10 deficient mice[J].Hepatology, 2011, 54 (3) :846-856.

[12]DOMINGUEZ M, MIQUEL R, COLMENERO J, et al.Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis[J].Gastroenterology, 2009, 136 (5) :1639-1650.

[13] BERTOLA A, MATHEWS S, KI SH, et al.Mouse model of chronic and binge ethanol feeding (the NIAAA model) [J].Nat Protoc, 2013, 8 (3) :627-637.

[14]KI SH, PARK O, ZHENG M, et al.Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding:role of signal transducer and activator of transcription 3[J].Hepatology, 2010, 52 (4) :1291-1300.

[15] BERTOLA A, PARK O, GAO B.Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury:A critical role for E-selectin[J].Hepatology, 2013, 58 (5) :1814-1823.

[16]LI H.The regulation of liver fibrosis by immune cells[J].J Clin Hepatol, 2012, 28 (1) :74-77. (in Chinese) 李海.免疫细胞对肝脏纤维化的调控作用[J].临床肝胆病杂志, 2012, 28 (1) :74-77.

[17]INOKUCHI S, TSUKAMOTO H, PARK E, et al.Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrowderived and endogenous liver cells in mice[J].Alcohol Clin Exp Res, 2011, 35 (8) :1509-1518.

[18]JEONG WI, PARK O, GAO B.Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis[J].Gastroenterology, 2008, 134 (1) :248-258.

[19]McKILLOP IH, SCHRUM LW.Role of alcohol in liver carcinogenesis[J].Semin Liver Dis, 2009, 29 (2) :222-232.

[20]ESFANDIARI F, MEDICI V, WONG DH, et al.Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanolfed cystathionine beta synthase-deficient mouse[J].Hepatology, 2010, 51 (3) :932-941.

[21]DOLGANIUC A, PETRASEK J, KODYS K, et al.MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice[J].Alcohol Clin Exp Res, 2009, 33 (10) :1704-1710.

[22]JUNG Y, BROWN KD, WITEK RP, et al.Accumulation of hedgehogresponsive progenitors parallels alcoholic liver disease severity in mice and humans[J].Gastroenterology, 2008, 134 (5) :1532-1543.

[23]DALAKAS E, NEWSOME PN, BOYLE S, et al.Bone marrow stem cells contribute to alcohol liver fibrosis in humans[J].Stem Cells Dev, 2010, 19 (9) :1417-1425.

[24]SOYKA M, ROSNER S.Emerging drugs to treat alcoholism[J].Expert Opin Emerg Drugs, 2010, 15 (4) :695-711.

[25]ADDOLORATO G, LEGGIO L.Safety and efficacy of baclofen in the treatment of alcohol-dependent patients[J].Curr Pharm Des, 2010, 16 (19) :2113-2117.

[26]MATHURIN P, O’GRADY J, CARITHERS RL, et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis:meta-analysis of individual patient data[J].Gut, 2011, 60 (2) :255-260.

[27]RAMBALDI A, SACONATO HH, CHRISTENSEN E, et al.Systematic review:glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials[J].Aliment Pharmacol Ther, 2008, 27 (12) :1167-1178.

[28]KENDRICK SF, HENDERSON E, PALMER J, et al.Theophylline improves steroid sensitivity in acute alcoholic hepatitis[J].Hepatology, 2010, 52 (1) :126-131.

[29] di MAMBRO AJ, PARKER R, McCUNE A, et al.In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis[J].Hepatology, 2011, 53 (4) :1316-1322.

[30]de BK, GANGOPADHYAY S, DUTTA D, et al.Pentoxifylline versus prednisolone for severe alcoholic hepatitis:a randomized controlled trial[J].World J Gastroenterol, 2009, 15 (13) :1613-1619.

[31]WHITFIELD K, RAMBALDI A, WETTERSLEV J, et al.Pentoxifylline for alcoholic hepatitis[J].Cochrane Database Syst Rev, 2009, 4:CD007339.

[32]BOETTICHER NC, PEINE CJ, KWO P, et al.A randomized, doubleblinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis[J].Gastroenterology, 2008, 135 (6) :1953-1960.

[33]MATO JM, CAMARA J, FERNANDEZ de PAZ J, et al.S-adenosylmethionine in alcoholic liver cirrhosis:a randomized, placebo-controlled, double-blind, multicenter clinical trial[J].J Hepatol, 1999, 30 (6) :1081-1089.

[34]RAMBALDI A, GLUUD C.S-adenosyl-L-methionine for alcoholic liver diseases[J].Cochrane Database Syst Rev, 2006, 2:CD002235.

[35]FEDE G, GERMANI G, GLUUD C, et al.Propylthiouracil for alcoholic liver disease[J].Cochrane Database Syst Rev, 2011, 6:CD002800.

[36] KONG F, FENG D, GAO B.Hepatoprotective and anti-fibrotic functions of IL-22:therapeutic potential for the treatment of alcoholic liver disease[J].J Gastro Hepatol, 2013, 28 (Suppl 1) :56-60.

[37]BASS NM, MULLEN KD, SANYAL A, et al.Rifaximin treatment in hepatic encephalopathy[J].N Engl J Med, 2010, 362 (12) :1071-1081.

[38]SHIFFMAN ML, POCKROS P, McHUTCHISON JG, et al.Clinical trial:the efficacy and safety of oral PF-03491390, a pancaspase inhibitor—a randomized placebo-controlled study in patients with chronic hepatitis C[J].Aliment Pharmacol Ther, 2010, 31 (9) :969-978.

[39]SETH D, GORRELL MD, CORDOBA S, et al.Intrahepatic gene expression in human alcoholic hepatitis[J].J Hepatol, 2006, 45 (2) :306-320.

[40]TAM J, LIU J, MUKHOPADHYAY B, et al.Endocannabinoids in liver disease[J].Hepatology, 2011, 53 (1) :346-355.

[41]MOOKERJEE RP, WIESENTHAL A, ICKING A, et al.Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis[J].Gastroenterology, 2007, 132 (7) :2533-2541.

施引文献

资源附件(0)

访问统计